GILD (STOCKS)
Gilead Sciences Inc
$155.800000
+8.570000 (+5.82%)
Prev close: $147.230000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Daniel P. O'Day
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $193,248.32M
- Employees
- 17,600
- P/E (TTM)
- 21.72
- P/B (TTM)
- 8.08
- Dividend Yield
- 214.63%
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
10
Strong Buy
20
Buy
7
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$1.86 | $1.85 | +0.0134 | +0.73% |
|
Sep 2025 (Q3)
|
$2.47 | $2.17 | +0.2972 | +13.68% |
|
Jun 2025 (Q2)
|
$2.01 | $2.00 | +0.0120 | +0.60% |
|
Mar 2025 (Q1)
|
$1.81 | $1.82 | -0.0107 | -0.59% |
Financial Statements
| Revenues | $29.09B |
| Benefits Costs and Expenses | $19.20B |
| Cost Of Revenue | $6.19B |
| Costs And Expenses | $18.60B |
| Gross Profit | $22.90B |
| Nonoperating Income/Loss | $414.00M |
| Operating Expenses | $12.41B |
| Selling, General, and Administrative Expenses | $5.89B |
| Other Operating Expenses | $6.52B |
| Operating Income/Loss | $10.49B |
| Income/Loss From Continuing Operations After Tax | $8.11B |
| Income/Loss From Continuing Operations Before Tax | $9.89B |
| Income Tax Expense/Benefit | $1.78B |
| Income Tax Expense/Benefit, Deferred | -$97.00M |
| Net Income/Loss | $8.11B |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $8.11B |
| Net Income/Loss Available To Common Stockholders, Basic | $8.11B |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $6.50 |
| Diluted Earnings Per Share | $6.46 |
| Basic Average Shares | 1,245,000,000 |
| Diluted Average Shares | 1,264,000,000 |
| Assets | $58.53B |
| Current Assets | $17.87B |
| Inventory | $1.79B |
| Other Current Assets | $16.09B |
| Noncurrent Assets | $40.66B |
| Fixed Assets | $5.50B |
| Intangible Assets | $17.97B |
| Other Non-current Assets | $17.19B |
| Liabilities | $37.08B |
| Current Liabilities | $12.30B |
| Accounts Payable | $808.00M |
| Other Current Liabilities | $11.49B |
| Noncurrent Liabilities | $24.78B |
| Long-term Debt | $24.94B |
| Equity | $21.46B |
| Equity Attributable To Noncontrolling Interest | -$84.00M |
| Equity Attributable To Parent | $21.54B |
| Liabilities And Equity | $58.53B |
| Net Cash Flow From Operating Activities | $9.67B |
| Net Cash Flow From Operating Activities, Continuing | $9.67B |
| Net Cash Flow From Investing Activities | -$3.18B |
| Net Cash Flow From Investing Activities, Continuing | -$3.18B |
| Net Cash Flow From Financing Activities | -$4.22B |
| Net Cash Flow From Financing Activities, Continuing | -$4.22B |
| Exchange Gains/Losses | $32.00M |
| Net Cash Flow | $2.29B |
| Net Cash Flow, Continuing | $2.26B |
| Comprehensive Income/Loss | $8.07B |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $8.07B |
| Other Comprehensive Income/Loss | -$37.00M |